Cyclerion Therapeutics, Inc.
CYCN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,000 | $0 | $297 | $3,320 |
| % Growth | – | -100% | -91.1% | – |
| Cost of Goods Sold | $0 | $0 | $5,579 | $0 |
| Gross Profit | $2,000 | $0 | -$5,282 | $3,320 |
| % Margin | 100% | – | -1,778.5% | 100% |
| R&D Expenses | $286 | $1,515 | $5,979 | $37,636 |
| G&A Expenses | $5,342 | $8,132 | $12,858 | $20,620 |
| SG&A Expenses | $5,342 | $8,332 | $13,258 | $20,620 |
| Sales & Mktg Exp. | $0 | $200 | $400 | $0 |
| Other Operating Expenses | $0 | $3,104 | -$5,979 | $259 |
| Operating Expenses | $5,628 | $12,951 | $13,258 | $58,515 |
| Operating Income | -$3,628 | -$12,951 | -$18,540 | -$55,195 |
| % Margin | -181.4% | – | -6,242.4% | -1,662.5% |
| Other Income/Exp. Net | $571 | $358 | $294 | $3,548 |
| Pre-Tax Income | -$3,057 | -$12,593 | -$18,246 | -$51,647 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3,057 | -$5,263 | -$44,078 | -$51,647 |
| % Margin | -152.9% | – | -14,841.1% | -1,555.6% |
| EPS | -1.21 | -8.99 | -20.15 | -26.4 |
| % Growth | 86.5% | 55.4% | 23.7% | – |
| EPS Diluted | -1.21 | -8.99 | -20.15 | -26.4 |
| Weighted Avg Shares Out | 2,518 | 2,338 | 2,173 | 1,957 |
| Weighted Avg Shares Out Dil | 2,518 | 2,338 | 2,173 | 1,957 |
| Supplemental Information | – | – | – | – |
| Interest Income | $208 | $358 | $294 | $0 |
| Interest Expense | $0 | $0 | $0 | $16 |
| Depreciation & Amortization | $0 | $65 | $65 | $472 |
| EBITDA | -$3,628 | -$9,582 | -$18,475 | -$53,842 |
| % Margin | -181.4% | – | -6,220.5% | -1,621.7% |